Critical Update: ADMA Biologics Shareholders Can Pursue Legal Action Due to Misleading Practices

Alert for ADMA Biologics Shareholders

Recent developments highlight serious concerns for shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA). The Gross Law Firm has officially announced its initiative to inform stakeholders about a class action lawsuit directed at the company, particularly for those who acquired shares between August 9, 2024, and March 25, 2026.

Overview of the Lawsuit

The allegations raised in the lawsuit detail a series of potentially misleading actions taken by ADMA Biologics. The core claims argue that the company's executives issued significantly false or deceptive statements while failing to disclose important facts. Notably, it has been asserted that ADMA engaged in undisclosed related party transactions and employed questionable practices, such as channel stuffing, to inflate its revenue figures artificially.

Additionally, the lawsuit suggests significant deficiencies in ADMA's internal controls, which could imply that the company's assertions regarding its business practices and prospects were anchored in misleading information during the class period. Given the nature of these allegations, impacted shareholders will have the opportunity to pursue restitution for their investment losses.

Important Dates and Steps to Follow

Shareholders who acquired shares of ADMA during the specified period are urged to act promptly. The deadline to apply for the role of lead plaintiff in this action is set for August 10, 2026. Being a lead plaintiff is not a prerequisite for participating in potential recovery, and involvement in this case comes at no cost or obligation to shareholders.

To facilitate participation, interested shareholders can register their information via the following link: ADMA Biologics Loss Submission Form.

Upon registration, shareholders will gain access to a portfolio monitoring tool that will keep them updated on the case's progression. This communication tool aims to ensure that stakeholders are fully aware of key developments and their potential implications for recovery efforts.

Role of The Gross Law Firm

The Gross Law Firm, renowned for its dedication to safeguarding investor rights, stands poised to represent those affected by alleged corporate misconduct. Their commitment extends to ensuring that companies adhere to ethical business standards while promoting responsible corporate citizenship. In instances where misleading statements or omissions lead to inflated stock prices, The Gross Law Firm seeks to recover losses on behalf of investors.

For those who wish to discuss their options or inquire further, The Gross Law Firm encourages direct contact. Interested individuals can reach out via email at [email protected] or by calling (646) 453-8903. The firm's New York office is located at 15 West 38th Street, 12th floor, New York, NY 10018.

Conclusion

The legal landscape for ADMA Biologics shareholders is evolving, and with it comes an opportunity for accountability and recovery. As shareholders navigate this challenging situation, being informed and proactive will be crucial to safeguarding their investments. Don't hesitate to take action if you're among those affected; now is the time to ensure your voice is heard within this class action lawsuit.